Profusa
Manufacturing · California, United States · Employees
View Company Info for Free
Overview
Headquarters
626 Bancroft Way Ste A, Berkeley, Califo...Phone Number
(415) 655-9861Website
www.profusa.comRevenue
-Stock Symbol
PFSAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Profusa
Profusa, Inc. is a pioneering company focused on developing tissue-integrating biosensors for the continuous monitoring of body chemistries. Their flagship product, the Lumee Oxygen Platform, has received a CE Mark for marketing in the European Union and is aimed at providing real-time monitoring of tissue oxygen levels. Profusa targets healthcare providers and researchers interested in innovative technologies for improving clinical management and remote patient monitoring. The company has gained recognition for its contributions to the biochemical sensors market and aims to further commercialize its leading-edge technology.Explore more
Profusa Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Profusa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Profusa recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Profusa, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Profusa has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Profusa launches new products
Click to see if Profusa had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Profusa has new funding data
Congratulate Masked Content for being promoted to Masked Content at Profusa
Check out if Profusa is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Profusa
Compare insights from companies similar to Profusa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Profusa is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Profusa is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Profusa.
Profusa financials insights
Gather financial insights about Profusa, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Debt
$1.2M
2013
Private Equity
$2.8M
Series A
$2.8M
2015
Private Equity
$11.3M
Series B
$13.2M
2016
Grant
$7.5M
2018
Series C
$45M
2020
Debt
$1M
2025
Stock/Share Issuance
$100M
Profusa Tech Stack
A closer look at the technologies used by Profusa
Most Recent Scoops
Funding
Funding
Funding
Profusa has received an SBA PPP loan for $1-2 million from Stearns Bank National Association.
Event
Profusa recently attended the 2019 HLTH conference, which was held October 27-30, 2019 in Las Vegas, NV.
Events
New Hire
Executive Move
Hesham Younis has been named Head of Business Development. Hesham is responsible for strengthening commercialization potential across markets and driving licensing and partnerships. Previously Younis served as the Vice President, Marketing at Cardinal Health.
Executive Moves, New Hire, Personnel Moves
New Hire
Executive Move
Executive Moves, New Hire, Personnel Moves
Profusa News & Media
Profusa Receives Favorable Nasdaq Listing Determination
BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announced that, by letter dated May 6, 2026, the Nasdaq Hearings Panel granted the Company’s request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market. The Company’s continued listing on Nasdaq isProfusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunitiesProfusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applicationsProfusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Profusa
Sign Up For FreeTo access detailed company insights
Profusa, Inc. is a pioneering company focused on developing tissue-integrating biosensors for the continuous monitoring of body chemistries. Their flagship product, the Lumee Oxygen Platform, has received a CE Mark for marketing in the European Union and is aimed at providing real-time monitoring of tissue oxygen levels. Profusa targets healthcare... Read More
